A new clinical study shows that a three-year, structured exercise program initiated shortly after the completion of adjuvant chemotherapy significantly improves disease-free survival (DFS) for patients treated for colon cancer. The findings also suggest a positive impact on overall survival (OS), although further analysis is ongoing.
The study, known as the CHALLENGE trial (NCT00819208), was funded by the Canadian Cancer Society and additional partners. Researchers evaluated the effects of regular physical activity in over 900 patients with high-risk stage II or stage III colon cancer who had completed standard chemotherapy.
Participants were randomized to receive either usual care or to participate in a three-year exercise program involving weekly structured aerobic physical activity sessions, along with guidance and support to maintain their fitness and adherence to the regimen over time.
The primary outcome, disease-free survival—defined as the time from randomization until relapse, secondary cancer, or death from any cause—was significantly extended in the group following the exercise protocol. Though precise statistical data is pending peer-reviewed publication, preliminary reports indicate a clear survival benefit.
In addition to prolonging DFS, the findings suggest improvements in quality of life and physical function, reinforcing the concept that lifestyle interventions can complement traditional medical treatments in oncology. The study stands as one of the most rigorous efforts to date assessing the role of exercise in cancer survivorship.
These results underscore the importance of integrating physical activity into post-treatment care plans for colon cancer patients, and support the development of clinical guidelines that prompt healthcare providers to encourage active lifestyles for those in remission.
The research continues to evaluate long-term benefits and overall survival differences, with results expected to inform future recommendations for cancer survivorship care.
Source: https:// – Courtesy of the original publisher.
